NVN Liquidation, Inc. (NOVNQ)
- Previous Close
0.0008 - Open
0.0008 - Bid --
- Ask --
- Day's Range
0.0008 - 0.0008 - 52 Week Range
0.0000 - 1.3786 - Volume
14 - Avg. Volume
12,587 - Market Cap (intraday)
22,412 - Beta (5Y Monthly) 1.65
- PE Ratio (TTM)
-- - EPS (TTM)
-1.2500 - Earnings Date Apr 29, 2024 - May 3, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
NVN Liquidation, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. NVN Liquidation, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was formerly known as Novan, Inc. and changed its name to NVN Liquidation, Inc. in October 2023. The company was incorporated in 2006 and is headquartered in Durham, North Carolina. On July 17, 2023, NVN Liquidation, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
www.novan.comRecent News: NOVNQ
Performance Overview: NOVNQ
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NOVNQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NOVNQ
Valuation Measures
Market Cap
22.41k
Enterprise Value
-8.67M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.00
Price/Book (mrq)
--
Enterprise Value/Revenue
-0.35
Enterprise Value/EBITDA
0.32
Financial Highlights
Profitability and Income Statement
Profit Margin
-128.61%
Return on Assets (ttm)
-25.84%
Return on Equity (ttm)
-2,098.89%
Revenue (ttm)
24.92M
Net Income Avi to Common (ttm)
-32.05M
Diluted EPS (ttm)
-1.2500
Balance Sheet and Cash Flow
Total Cash (mrq)
12.54M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-31.32M